Related Experiment Video
Updated: Mar 18, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Correlation between vascular endothelial growth factor and long-term prognosis in patients with acute myocardial
Jiamin Niu1, Xia Han1, Huaxin Qi1
1Department of Cardiology, Laiwu People's Hospital, Laiwu, Shandong 271100, P.R. China.
Insights
High plasma vascular endothelial growth factor (VEGF) levels 7 days after acute myocardial infarction (AMI) improve long-term prognosis. Low VEGF levels are independent risk factors for major adverse cardiovascular events (MACE) in AMI patients.
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Clinical Research
Background:
- Acute myocardial infarction (AMI) poses a significant risk for major adverse cardiovascular events (MACE).
- Vascular Endothelial Growth Factor (VEGF) plays a crucial role in angiogenesis and tissue repair following ischemic events.
- Understanding biomarkers that predict MACE in AMI patients is vital for improving patient outcomes.
Purpose of the Study:
- To investigate the correlation between plasma VEGF levels and MACE in patients with AMI.
- To determine if VEGF levels measured early after AMI onset can predict long-term cardiovascular events.
- To identify VEGF as a potential prognostic biomarker in AMI.
Main Methods:
- A cohort of 124 AMI patients undergoing percutaneous coronary intervention (PCI) was studied.
- Plasma VEGF levels were measured 7 days post-AMI using ELISA.
- Patients were categorized into low (L) and high (H) VEGF groups and followed for MACE over 12 months.
Main Results:
- The high VEGF group showed a significantly reduced incidence of MACE at 6 months compared to the low VEGF group.
- Patients with no MACE (N-MACE) had significantly higher serum VEGF concentrations than those with MACE.
- Reduced VEGF levels were identified as an independent risk factor for MACE (β=1.243; P=0.026).
Conclusions:
- Elevated plasma VEGF levels 7 days after AMI onset are associated with a favorable long-term prognosis.
- Low plasma VEGF levels serve as an independent risk factor for MACE in AMI patients.
- VEGF measurement may aid in risk stratification and management of AMI patients.
Abstract:
The aim of the present study was to investigate the correlation between plasma the levels of vascular endothelial growth factor (VEGF) and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI). A total of 124 patients with AMI undergoing emergency percutaneous coronary intervention (PCI) were selected, and plasma VEGF levels were measured 7 days after the onset of AMI using an enzyme-linked immunosorbent assay. The patients were divided into the L (≤190 pg/ml VEGF) and H (>190 pg/ml VEGF) groups, and were followed up every 2 months for an average of 12 months. MACE were recorded during follow-up. On the basis of these results, the patients were further divided into the MACE and non-MACE (N-MACE) groups, and the serum VEGF concentration was compared between the two groups. At the 6-month follow-up, the incidence of MACE in the H group was found to be significantly reduced compared with the L group. The serum VEGF concentration in the N-MACE group was significantly higher compared with the MACE group. Multinomial logistic regression revealed that reduced VEGF levels (β=1.243; 95% CI, 1.018-1.326; P=0.026) were independent risk factors for MACE. In conclusion, high plasma VEGF levels at 7 days after AMI onset facilitate the long-term prognosis in the same infarct zone in patients with AMI, while low plasma VEGF levels are independent risk factors for MACE.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
01:30Acute Coronary Syndrome III: Diagnostic Studies